Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › fingolimod

fingolimod

0 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of fingolimod

19 trials tracked of fingolimod: 16 in phase 3 or 4 and 1 with published results. The most-cited published study has 71 citations.

19Trials tracked
16Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 10 Phase 3 6 Phase 2 2 Phase 1 1
  1. Phase 3 Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis Completed · 71 cited
  2. Phase 4 A 3-year Multi-center Study to Describe Changes of OCT Parameters Under Treatment With Gilenya® Completed
  3. Phase 4 A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod Completed
  4. Phase 4 Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks Completed
  5. Phase 4 Follow up Study of Patients on Fingolimod Who Were Enrolled in the Original Biobank Study (CFTY720DDE01) Completed
  6. Phase 4 A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis Completed
Show 13 more trials
  1. Phase 4 Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC) Completed
  2. Phase 4 Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis. Completed
  3. Phase 4 A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720 Completed
  4. Phase 4 Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change Completed
  5. Phase 4 Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms Completed
  6. Phase 3 Evaluating of the Effect of Fingolimod With Fish Oil on Relapsing-Remitting Multiple Sclerosis Patients Completed
  7. Phase 3 Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis Completed
  8. Phase 3 Effect of Treatment With Fingolimod on the Immune Response Following Seasonal Flu Vaccination and Tetanus Booster Injection in Patients With Relapsing Multiple Sclerosis (MS) Completed
  9. Phase 3 Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis Completed
  10. Phase 3 Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients. Completed
  11. Phase 2 Fingolimod in Schizophrenia Patients Completed
  12. Phase 2 An Extension Study of the Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing Multiple Sclerosis Completed
  13. Phase 1 Fingolimod as a Treatment of Cerebral Edema After Intracerebral Hemorrhage Completed

Showing the 19 most-cited and recently-updated of 19 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
No published articles yet for this medication. Check back soon.